

Remarks

The application is subject to a restriction requirement. Group II hereby is elected without traverse. Accordingly, Claims 1 and 2 (and, thus, claims which are dependent from them or refer to their definitions) are amended to delete non-elected subject matter. Claim 3 is canceled as redundant following the amendment of Claim 2. Claim 21, which includes process (a) of Group II and additional processes of Group IV, has been withdrawn and amended to include all the limitations of product Claim 1 so that it is commensurate in scope with Claim 1, as amended. In addition, an omitted "or" has been inserted. Claim 23 is amended to insert an omitted "n" in the definitions.

An election of species is required. The species elected is that of Example 2, at page 35 of the description. New Claim 27, drawn to that species has been provided. No new subject matter has been added by amendment. Pending claims which read on the elected species or which provide processes or intermediates relative to the elected species are Claims 1-2, 4-8, 10, 13-15, 18, 20, 21 [processes (a) and (b)], 22 and 26-27.

It is believed that no fee is required for this response; however, the Commissioner hereby is authorized to charge any requisite fee for the response to Deposit Account No. 05-0840. The Examiner is encouraged to telephone the undersigned if it is useful to expedite any aspect of the prosecution.

Respectfully submitted,

/Thomas E. Jackson/

Thomas E. Jackson
Patent Attorney
Registration No. 33064
Phone: 317/277-3735

Eli Lilly and Company
Patent Division/
P.O. Box 6288
Indianapolis, Indiana 46206-6288

8 February 2008